Cefdinir Capsule
NDC Package 72189-308-20

11-digit billing NDC: 72189030820 · Billing unit: EA · 20 EA per package

Package Information

Cefdinir capsules is to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, Cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. This formulation utilizes a capsule delivery system. Marketed by Directrx, this product is identified by NDC 72189-308 and is authorized under FDA application ANDA210220.

Identification & Billing

NDC Package Code
72189-308-20
Package Description
20 CAPSULE in 1 BOTTLE
Product Code
11-Digit Billing Format
72189030820
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
20 EA
RxNorm Crosswalk
RxCUI: 200346 - cefdinir 300 MG Oral Capsule

Clinical Specifications

Proprietary Name
Cefdinir
Non-Proprietary Name
Cefdinir
Substance Name
Cefdinir
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, Cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.Adults and AdolescentsCommunity-Acquired PneumoniaCaused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES).Acute Exacerbations of Chronic BronchitisCaused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains).Acute Maxillary SinusitisCaused by Haemophilus influenzae (including β-lactamasen producing strains), Streptococcus pneumonia (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains).NOTE: For information on use in pediatric patients, see PEDIATRIC USEand DOSAGE AND ADMINISTRATION.Pharyngitis/TonsillitisCaused by Streptococcus pyogenes (see CLINICAL STUDIES).NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever.Uncomplicated Skin and Skin Structure InfectionsCaused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes.Pediatric PatientsAcute Bacterial Otitis MediaCaused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumonia (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains).Pharyngitis/TonsillitisCaused by Streptococcus pyogenes (see CLINICAL STUDIES).NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever.Uncomplicated Skin and Skin Structure InfectionsCaused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes.

Regulatory & Marketing

Labeler Name
Directrx
Product Type
Human Prescription Drug
FDA Application #
ANDA210220
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
02-02-2022
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (72189-308). Click a package code to view its specific billing and regulatory data.

14 CAPSULE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72189-308-20 identifies a specific commercial package of 20 capsule in 1 bottle of Cefdinir, a human prescription drug labeled by Directrx. This product is billed for "EA" each discreet unit and contains an estimated amount of 20 billable units per package. This capsule is formulated for oral use and contains cefdinir as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Directrx on February 02, 2022. The current certification is valid through December 31, 2026.

How is this Directrx product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72189030820. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 20 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72189-308-20
11-Digit CMS (5-4-2)
72189-0308-20

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.